June 24th, 2021 • Live Online & Interactive

The Covid 19 pandemic revealed significant lessons for the healthcare systems all over the world.

While we all realized that even the most advanced health systems were unprepared to cope with a pandemic, we also saw that the vulnerabilities in health systems can have profound implications not only for public health but for the economic progress as well.

The strong interconnection between human health and economy will put significant challenges for the Future of Health Care systems and the economic growth.

Τhe ageing population and the increased demand for long term care, antimicrobial resistance, prevention of non-communicable disease, are only some of the challenges that countries and policy makers should take into consideration in order to improve our healthcare systems and accelerate our economy.







international speakers




live viewers




With the attendance of more than 250 delegates and 28 distinguished speakers from Greece and abroad, the conference «The Future of Healthcare in Greece» was concluded with great success.

The conference was organized for the 11th consecutive year with great success by Health Daily and BOUSSIAS under the special theme: “Human Health and Economic growth: The missing link”. Representatives from the Government and European Parliament, OECD, Academics from LSE, Harvard Medical School, University of Oxford, Geneva Medical School and University of Athens as well as Pharma industry representatives presented the lessons learned from the Covid -19 pandemic and discussed the future needs for a Healthcare system, more inclusive, resilient, and fairer.

Highlights of the conference was the opening speech of the Minister of Finance, Christos Staikouras who presented a series of initiatives to support the country’s health system, and the speech of Thanasis Kontogiorgis, Secretary General of Government Coordination who presented in detail the government plan, including the National Plan for Recovery and Resilience Greece 2.0.

Significant intervention was made by the Vice-President of the European Parliament, Dimitris Papadimoulis, who said that now is the right time to build a strong and common European Health Policy and by the Secretary General of the Ministry of Health, Marios Themistokleous who talked about the main challenges of the public health sector and the main directions that should be followed designing the new Primary Healthcare System Services.

Finally, Professor Nikos Polyzos concluded at the end of the conference: “The pandemic has highlighted problems in national health systems that have extended to economies, but also to political leaderships that were sometimes based on experts and sometimes not. It seems that in the future there will be more support for public health, primary health care, but also support for innovation both in the field of medicine and in the hospital sector.”

We are pleased to announce that the 11th Future of Healthcare in Greece, conference will take place on Thursday, June 23, 2022!


The main topics of the conference will include:

  • Human Health and Economic Growth: The Missing Link
  • Economy and Healthcare Systems through Pandemic – Lessons Learned   
  • Preparing the World for Future Pandemics-The Rome G20 Declaration 
  • Complex and Cross-Borders Challenges Ahead  
  • Greek Healthcare System In 2021 And Beyond


Opening Speech

Christos Staikouras

Minister of Finance, Greece


Lorena Androutsou, MSc, PhD, Programme management Agent European Commission, Luxembourg, Visiting Lecturer in Health Services Management, University of Neapolis, Cyprus
Ioannis Boukovinas, Medical Oncologist, Head of Oncology Unit in Bioclinic, Chairman of Hellenic Society of Medical Oncologists
Emmanouil Dermitzakis, Professor of Genetic Medicine and Development, University of Geneva Medical School, Director, Health 2030 Genome Center
Othon Iliopoulos, Associate Professor of Medicine, Harvard Medical School
Michalis Kakouros, Access Value Lead, Roche
Panos Kanavos, Associate Professor, Deputy Director, LSE Health, Department of Social Policy, London School of Economics
Thanasis Kontogeorgis, Secretary General of Coordination-Presidency of the Government
Nikos Kostaras, General Manager, IQVIA
Panagiotis Liargovas, Professor at the Department of Economics, University of Peloponnese, President and Scientific Director of the Center for Planning and Economic Research (KEPE)
Athina Linos, Professor, Medical School, University of Athens, President of the Institute of Preventive Medicine Environmental and Occupational Health
David Morgan, Senior Health Policy Analyst, Health Policy Division Organisation for Economic Co-operation, and Development
Yannis Natsis, Policy Manager for Universal Access and Affordable Medicines, European Public Health Alliance (EPHA), Member of The Management Board at European Medicines Agency (EMA)
Olympios Papadimitriou, President Hellenic Association of Pharmaceutical Companies (SFEE)
Dimitris Papadimoulis, Vice-President, European Parliament, Member of the European Parliament’s “Progressive Caucus” steering committee
Elpida Pavi, Professor, Department of Public Health Policy, Dean of School of Public Health, University of West Attica
Vasilios Pentafragas, Executive Director, Panhellenic Pharmaceutical Association (PEF)
Andreas Pollner, Managing Director & CDH Pharma Cluster Bayer Hellas
Nikos Polyzos, Prof. of Health Services Management, Dept. of Social Management, University of Thrace
Peny Retsa, Market Access & External Relations Director at AbbVie
Laura Sochas, Dept. of Social Policy and Intervention, University of Oxford
Marios Themistokleous, General Secretary of Primary Care services, Ministry of Health
George Tousimis, Vice-President, Pharma Innovation Forum
George Tsiakalakis, Director, Greek Patients Association
Sotiris Vandoros, Reader in Health Economics at King’s College London, and Adjunct Associate Professor at Harvard University.
Alkiviadis Vatopoulos, Professor in Public Health Microbiology at the Department of Public Health Policy, School of Public Health, University of West Attica
Anouk De Vroey, Head Government Affairs & Policy Pharmaceuticals EMEA & Vaccines – Janssen
Dimitris Zografopoulos, Senior Legal Counsel – DPO at Greek Ministry of Health


Statements of Key Leads

Target group

Senior government officials / Representatives of healthcare institutions / Public and private health services providers / Financial and corporate organizations / Senior executives from health and pharma industries / Health economists / Health Policy experts / Doctors -Nurses / Healthcare professionals / Patient advocates & patient group representatives / Academics / Researchers / Journalists


Grand Sponsor

Our vision “Health for All – Hunger for None” 

Advancing life – that’s what we at Bayer are all about. We put ourselves to the test day in, day out. All together. All over the world. With enthusiasm for new ideas. 

Bayer is a Life Science company with a more than 150-year history of Innovation and core competencies in the areas of health care and agriculture. Thus, we are in the unique position to provide solutions that serve our most basic human needs – health and food. 

Bayer Hellas is the subsidiary of Bayer AG in our country. Our company is operating since 1955, in researching, developing and marketing the locally approved products of Bayer AG, in all the three divisions.   

Find out more about our company in  


AbbVie is a global research-driven biopharmaceutical company. We are committed to developing innovative advanced therapies for some of the world’s most complex and serious health issues. AbbVie’s mission is to leverage our experience, dedicated people and unique approach to innovation to significantly improve treatments across five therapeutic areas: Immunology, Hematology, Eye Care, Neuroscience and Aesthetics. More than 47,000 AbbVie employees around the world work daily to develop therapeutic options for patients worldwide.

In Greece, AbbVie since its inception in 2013, has been operating, apart from the commercial branch, an international clinical research hub. The Site Management & Monitoring Operations hub is responsible for a cluster of 14 countries from Europe, Middle East and Africa, and employs more than 40 scientists from different fields. This allows AbbVie to conduct more than 45 clinical studies in our country in a total investment of over 2.5 million € on an annual basis.

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. Please visit  and follow the Company on Twitter @AstraZeneca

Bioiatriki Healthcare Group  is a Greek company, founded in 1981 with the vision to bring equal access to high quality healthcare services for everyone. We are today, the leading privately-owned Primary Healthcare Services provider in Greece, consisting of 56 autonomous Diagnostic Centers in Greece and Cyprus, 2 Clinics in Athens and Thessaloniki, 1 International Patient Center and 7 Dental Clinics.

In our premises we receive more than 3,000,000 patient visits per year. Our success lies in the expertise of our 3,000 highly-qualified employees, 700 of whom are doctors and scientists. Despite current challenges, we continue our expansion with a €45,000,000 multidimensional investment program in technological & medical equipment. Additionally, more than 450.000 people have benefited from our corporate responsibility programs.

Find out more at

IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services dedicated to using analytics and science to help healthcare stakeholders find better solutions for their patients. Solutions are powered by the IQVIA CORE™, which combines big data, advanced technology, analytics and extensive industry knowledge. Formed through the merger of IMS Health and Quintiles, IQVIA has approximately 70,000 employees worldwide. Learn more at

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart

We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at,

Follow us at

Janssen-Cilag Pharmaceutical S.A.C.I. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Doing now what patients need next

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Learn more at


Βristol-Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases.

Each day, our employees around the world work together for patients – it drives everything we do. We are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through our R&D organization, we have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate our work.

For more information visit our website

PHILIPS: A focused leader in health technology

Philips, with more than 125 years of experience worldwide and more than 90 years of presence in Greece, is at the forefront of medical care.

Guided by deep clinical and consumer insights, Philips delivers innovations and integrated solutions that provide better healthcare outcomes, reduce costs, and improve the working conditions of healthcare professionals.

Our aim is to improve 2.5 billion lives per year by 2030.

Η POTAMITISVEKRIS αποτελεί μία από τις μεγαλύτερες δικηγορικές εταιρείες της Ελλάδος, είναι οργανωμένη στα πρότυπα αντίστοιχων εταιρειών του εξωτερικού, ενώ βασίζεται στον πυλώνα της συμβουλευτικής δικηγορίας και σε αυτόν της δικαστικής επίλυσης. Καλύπτει όλο το φάσμα των νομικών αναγκών μιας επιχείρησης και είναι πιστοποιημένη από την LRQA με το διεθνές πρότυπο ISO 9001. Η εταιρεία είναι ευρέως αναγνωρισμένη και έχει βραβευτεί από τον διεθνή νομικό οδηγό Chambers & Partners, ως «Δικηγορική Εταιρεία της Χρονιάς» για τα έτη 2012, 2014, 2020 & 2021!

About Takeda Pharmaceutical Company

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in healthcare in approximately 80 countries.

For more information:

Under the Auspices

Η Π.Ε.Φ. αντιπροσωπεύει τις απόψεις της εγχώριας παραγωγικής φαρμακοβιομηχανίας, έναν τομέα με στρατηγική σημασία για την εθνική οικονομία. Οι φαρμακοβιομηχανίες-μέλη της ΠΕΦ, διατηρούν 29 παραγωγικές μονάδες στην Ελλάδα αναπτύσσοντας και παράγοντας φάρμακα άριστης ποιότητας με τη χρήση τεχνολογίας αιχμής σύμφωνα με τα υψηλά ευρωπαϊκά ποιοτικά πρότυπα GMPs. Οι ελληνικές φαρμακοβιομηχανίες πραγματοποιούν σημαντικές εξαγωγές σε πάνω από 85 χώρες, υλοποιούν προγράμματα σημαντικών επενδύσεων στους τομείς του ποιοτικού ελέγχου και της διασφάλισης της παραγωγικής διαδικασίας, με αποτέλεσμα την ανταγωνιστική παρουσία της στις διεθνείς αγορές με εξαγωγές.

SFEE, The Hellenic Association of Pharmaceutical Companies is one of the most innovative, productive and extravert branches of national economy. It represents more than 90% of the pharmaceutical companies’ active in our country. The 65 member-companies (22 Hellenic and 43 multinational companies), constantly invest in the development of effective medicines and treatments, in order to secure every citizen’s right to health and to a better standard of living. SFEE established in 1982 and for more than 38 years now has championed the common interests of patients, pharmaceutical companies and their workforce.

PhRMA Innovation Forum (PIF) represents 26 leading Research and Development Companies, which work together to meet the medical needs of patients in Greece, to help them have a long, healthy and productive life.

PIF member companies represent 60% of the Greek pharmaceutical market and the majority of domestic investments in international clinical trials with over € 90 million in investments in Greece over the last five years, while employing 3,000 highly trained professionals.

Our common vision is to use our global experience and ensure that patients in Greece have adequate and timely access to the treatment they need.

Our commitment is to work with all relevant sectors in order to contribute to the creation of a fair, democratic, transparent, stable and sustainable health system, which will also reward pharmaceutical innovation.

The Association of Pharmaceutical Products and Jobs Representatives (SAFEE) represents and expresses the views of a large number of Greek representatives and has a strong presence in the medicinal products and para-pharmacies sector.

The Association was established in 2000 to contribute effectively, with targeted proposals/interventions in the Greek pharmaceutical market, towards improving its function and, therefore, strengthening the national economy.

Media Partner

Media Sponsors

Livestreaming by

CONEQ provides technical equipment and services to any kind of event. With our Simultaneous Interpretation Systems, Conference Systems, AudioVisual Equipment we support events and provide the best service to our customers. Our professionalism, our high quality of service and state of the art equipment offered to over 600 large and of great significance conferences during the last 5 years have certainly contributed to our constant uptrend. Call us at (+30) 211 2163453. or email us at [email protected]

Organized by

Contact us

Sponsorships & Registrations
Chrysoula Kordouli, Τ: 210 6617777 (ext. 204), +30 6946236795, [email protected]

Nelly Kapsi, T: +30 210 6617 777 (ext. 289), +30 6977731311, E: [email protected]
Renata Valsami, T: +30 210 6617 777 (ext. 289), E: [email protected]


  338, Kleisthenous Str. 15344, Gerakas, Attiki, Greece
  +30 210 6617777
  +30 210 6617778